Replies to post #4145 on 22nd Century Group Inc (XXII)

[timorr]

I agree that the really big money is in overseas tobacco and our government has nothing to do with it. I'm convinced we'll see a 10 bagger from here and more.

[Justfactsmam]

Actually I left out main point in IGEN vs. ROCHE...private equity funded the Patent suit all the way...there was no shortage of capital for IGEN, who at the time only had just over $1m in cash. Shareholders made out handsomely as did private equity partners.

Key there...Roche had already incorporated Igen technology into its product used by 7,000 diagnostic customers world-wide.

Not to dis-similar to a situation where Big Tobacco if they violated and used XXII technology in its cigarettes worldwide...IMHO settlement would require big tobacco to buy XXII.

[sons4]

"IMHO...there will not be any VLN designation for at least 4 years when the FDA completes its study."

IMO this study is to determine to regulate nicotine in all cigarettes. This does NOT mean that XXII will not get approval to sell these cigarettes in the US before the trials are completed. They are filing the applications to do so this upcoming quarter. This approval shouldn't take 4 years because I'm sure this was discussed in the meeting with the FDA back in June.

FDA Meeting

The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) requested to have a meeting with 22nd Century to discuss the company’s proprietary products. 22nd Century agreed to meet with the FDA on June 17, 2013.



Goodrich Tobacco has developed two proprietary modified risk cigarettes, referred to as BRAND A and BRAND B, which the company believes are less harmful than conventional cigarettes. The company is in the process of preparing two modified risk applications to be filed with the FDA in accordance with FDA guidelines to seek FDA authorization to market BRAND A and BRAND B as modified risk cigarettes. BRAND A is a very low nicotine (VLN) cigarette containing approximately 95 percent less nicotine than leading brands. BRAND B is a low-tar cigarette with a relatively high nicotine content. The company expects to file one application by the end of 2013 and another in 2014.